Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A)

The vaccine contains polysaccharide from Neisseria meningitidis group C chemically linked to tetanus toxoid. This conjugation enables the polysaccharide to be processed by T‑cell‑dependent pathways, leading to robust B‑cell activation and the production of high‑affinity antibodies that specifically target the group C capsule, providing active, long‑lasting protection.

The dosing schedule for Neisvac‑C is determined by the prescribing healthcare professional based on age, vaccination history and local immunisation guidelines. The prescriber decides the number of doses, the interval between them and any booster requirements appropriate for the individual patient.

Safety data for Neisvac‑C in pregnancy are limited, so vaccination should only be considered when the potential benefit outweighs any theoretical risk. Breastfeeding is not a contraindication, but mothers should discuss vaccination with their healthcare provider to ensure appropriate timing and monitoring.

To place an order, submit an enquiry on the Neisvac‑C product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Neisvac‑C is a conjugate vaccine targeting serogroup C, offering T‑cell‑dependent immunity and long‑lasting protection. Compared with polysaccharide‑only vaccines, it generates higher‑affinity antibodies and immunological memory. Alternative conjugate products such as Menveo or Menactra cover additional serogroups (A, C, W, Y) and may be chosen based on regional disease patterns and vaccination schedules.

Neisvac‑C must be stored in a refrigerated environment between 2 °C and 8 °C. It should be kept in its original packaging to protect from light, must not be frozen or shaken, and any vial that has been frozen or exposed to temperatures above 8 °C should be discarded.

The vaccine is supplied as an injectable solution for intramuscular injection, typically administered into the deltoid muscle of the upper arm. The injection is performed by a qualified healthcare professional using aseptic technique, and the site should be observed for any immediate reactions.

Serious adverse events, although rare, include anaphylactic reactions, Guillain‑Barré syndrome and severe local reactions such as extensive swelling or tissue necrosis at the injection site. Patients should be monitored after vaccination, and any signs of severe allergy, neurological symptoms or unusual local reactions require prompt medical evaluation.

Neisvac‑C should not be administered to individuals with a known severe allergy to any component of the vaccine, including the tetanus toxoid carrier. Persons who have experienced a previous anaphylactic reaction to a meningococcal conjugate vaccine should also avoid it. Contraindications are determined by the prescriber based on medical history.